ReviewPhysiological research2026
Bioactive Peptides in Probiotic Fermented Foods: Structure-Activity Relationships and Cardiometabolic Protective Effects.
Review in Physiological research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bioactive peptides generated during probiotic fermentation have emerged as a complex class of food-derived molecules with multifaceted physiological effects relevant to cardiometabolic health. Recent advances in peptidomics, structural analysis, and mechanistic evaluation have revealed that fermentation with lactic acid bacteria, Bacillus species, or mixed cultures produces highly diverse peptide profiles whose activities depend on sequence motifs, hydrophobicity, charge distribution, and resistance to gastrointestinal degradation. These peptides modulate key pathways involved in vascular regulation, glucose metabolism, lipid handling, and inflammatory signaling. Evidence from cellular and animal models consistently demonstrates that selected short sequences inhibit angiotensin converting enzyme, enhance incretin bioactivity through dipeptidyl peptidase IV inhibition, reduce oxidative stress via direct radical scavenging and Nrf2 activation, attenuate inflammatory cascades by neutralizing endotoxin or interfering with immune receptor interactions, and influence lipid metabolism by interacting with bile acids or receptor-regulated transcription factors. Human trials, although heterogeneous in design and outcomes, suggest modest improvements in blood pressure, glucose tolerance, and lipid measures in specific populations, with notable geographical and genetic variability. Controversy remains regarding effect size, reproducibility, and translation of in vitro potency to physiological relevance due to variability in peptide abundance, digestion stability, and differences in habitual diet. Despite such limitations, emerging strategies in controlled fermentation, peptide enrichment, in silico prediction, and combined functional formulations indicate strong potential for targeted development of peptide-rich foods that support cardiometabolic resilience. Continued integration of structural analysis, mechanistic validation, and rigorously designed clinical studies will be essential to clarify their role within food-based preventive strategies.
Indexed as
Identifiers
42708862PMC13580679What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.